Unigef 250mg

Unigef 250mg Tablet is primarily used to help manage certain types of lung cancer by targeting specific cancer cells within the body. It is designed for patients with non-small cell lung cancer (NSCLC) that has specific genetic changes, aiming to support their treatment journey and enhance their overall well-being.

The active ingredient, Gefitinib, works by inhibiting the growth of cancer cells. It specifically targets the epidermal growth factor receptor (EGFR), which is involved in the development and progression of tumors. By blocking this receptor, Gefitinib may help slow down the growth of cancer cells, contributing to the management of the disease.

For best results, it is recommended to store Unigef tablets in a cool, dry place, away from direct sunlight and moisture. Consistency in taking the medication as prescribed is important for its effectiveness. Patients should be aware of precautions related to any existing health conditions and other medications they are taking, to avoid potential interactions.

Common side effects may include mild symptoms such as nausea, diarrhea, or skin reactions. These are generally manageable, but it is important to monitor any changes and discuss them with a healthcare professional.

This is general information, not a substitute for medical advice. Always consult a doctor/pharmacist and read the package leaflet.